TOKYO, – The first batch of Pfizer Inc.’s Kovid-19 vaccine arrived in Japan on Friday, with local media reporting that the official shot of the shots within days as the nation races to control a third wave of infection before the Olympic Games. Was approved.
A government health panel is due to discuss the vaccine later on Friday, when shots are expected to be green-lighted for formal approval. Kyodo News reported that the approval will come on Sunday.
Prime Minister Yoshihide Suga has said that the vaccination will start from the middle of next week, start with health workers, and the government hopes to have sufficient supplies for the entire population by mid-year.
An official from the Japanese Ministry of Health said that it could not confirm the report of the vaccine’s arrival due to security reasons.
Media sent news alerts on the arrival of the first batch of vaccines at Narita International Airport, near Tokyo, due to questions over the European Union’s willingness to allow Kovid-19 vaccines to leave their territory. The number of incoming doses was not reported.
The European Commission said on Thursday that it has so far approved all requests for export of Kovid-19 vaccines, including Japan, since it set up a mechanism to monitor vaccine flow on 30 January.
Pfizer applied for Japanese approval in December for its Kovid-19 vaccine, which is already administered in the United States, Singapore and other parts of the world.
The Japanese government has made adequate arrangements to vaccinate 72 million people, or 72 million people, of the vaccines made by the American pharmaceutical company and German partner BioNotech. It also has vaccine deals being developed by AstraZeneca Plc, Moderna Inc and Novavax Inc.
Japan has recorded about 410,000 coronovirus cases and 6,772 deaths so far, and is particularly racing to control infections beginning in July, ahead of the Tokyo Olympic Games.
After the third and deadliest wave of viruses at the end of last year, most of Japan is still in a state of emergency, although cases and fatalities have decreased in the last few weeks. (Reporting by Rocky Swift and Kiyoshi Takenka; Editing by Lincoln Feast.)